Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Report Overview
The total market value for the 15MM, which includes both cell therapies and established/traditional CLL therapies was $13.2 billion in 2021. Allogeneic stem cell transplant is becoming less popular due to high levels of morbidity and CAR-T seems an attractive replacement to induce long-term disease control.
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Know More about Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Forecast
The CLL– cell therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
Market Size (2021) | $13.2 billion |
Forecast Period | 2021-2031 |
Key Regions | · APAC
· Europe · Middle East · North America |
Leading Players | · Sian Wuhan Medical Technology Co Ltd
· (Bristol Myers Squibb) Celgene Corp · Autolus Therapeutics · Gilead · Kite Pharma (Gilead) |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Dynamics
More targeted therapies entering earlier lines of therapy may reduce patient numbers entering the R/R setting where cell therapy is expected to launch or may provide direct competition to cell therapy. However, CAR-T usage in patients with del17p/TP53 mutations will be driven by the unmet need for more treatments that can induce long-term disease control. Moreover, CAR-T is also an attractive option for R/R patients who have progressed on targeted therapy. This, in turn, will propel the market growth during the forecast period.
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Treatment
- More targeted therapies such as next-generation BTK and BCL2 inhibitors will provide more treatment options. However, patients with del17p/TP53 mutations tend to cycle through the available options quickly and relapse sooner.
- Young patients stand to benefit from time-limited therapy options as opposed to agents like Imbruvica that require daily treatment until progression. For instance, Venclexta plus Gazyva is designed to be completed within 12 months and induce long-term remission thereafter.
Buy Full Report for More Insights into the Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Treatment
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Segmentation by Regions
North America had the highest sales in 15MM in the CLL-cell therapies 15-market.
A few of the key regions in the market are APAC, Europe, Middle East, and North America.
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)
Buy the Full Report for More Regional Insights into the Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market -Competitive Landscape
Key future players in the cell therapy market in CLL consist mostly of small- to medium-sized biotech companies based in the US or China. This includes companies that are well-established in the CGT space outside of CLL, such as Juno Therapeutics approved in non-Hodgkin’s lymphoma [NHL]), and Kite Pharma among others.
A few of the major players in the chronic lymphocytic leukemia (CLL) – -cell therapies 15-market are:
- Sian Wuhan Medical Technology Co Ltd
- (Bristol Myers Squibb) Celgene Corp
- Autolus Therapeutics
- Gilead
- Kite Pharma (Gilead)
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Companies
Buy the Full Report to Know More about Companies in the Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)
- APAC
- Europe
- Middle East
- North America
Scope
- The report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action, and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by the 8 major markets.
- The forecast includes 8 countries for the period of 2021-2031.
- Seven markets are extrapolated obtaining a 15-market value for all CLL therapeutics.
Reasons to Buy
- Get cell therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Autolus Therapeutics
Sian Wuhan Medical Technology
Table of Contents
Frequently asked questions
-
What was the CLL–cell therapies 15-market size across the 8MM in 2021?
The total market value for the 15MM, which includes both cell therapies and established/traditional CLL therapies was $13.2 billion in 2021.
-
Which region had the highest sales in the 8MM CLL– cell therapies 15-market?
North America held the highest sales in the CLL–cell therapies 15-market across the 8MM in 2021.
-
Who are the leading players operating in the CLL–cell therapies 15-market?
A few of the major players in the CLL–cell therapies 15-market are Sian Wuhan Medical Technology Co Ltd, (Bristol Myers Squibb) Celgene CorpAutolus Therapeutics, Gilead, Kite Pharma (Gilead) among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.